PMID- 36200157
OWN - NLM
STAT- MEDLINE
DCOM- 20230519
LR  - 20230521
IS  - 1874-4702 (Electronic)
IS  - 1874-4672 (Linking)
VI  - 16
IP  - 5
DP  - 2023
TI  - Fathoming the Role of mTOR in Diabetes Mellitus and its Complications.
PG  - 520-529
LID - 10.2174/1874467215666221005123919 [doi]
AB  - Mechanistic/Mammalian target of rapamycin (mTOR) orchestrates cellular 
      homeostasis by controlling cell growth, proliferation, metabolism, and survival 
      by integrating various growth factors, nutrients and amino acids. Eccentric 
      synchronization of mTOR has been incriminated in various diseases/disorders like 
      cancer, neurodegenerative disorders, and diabetes mellitus and its complications. 
      Recent reports also highlight the role of mTOR in diabetes and its associated 
      complications. This review tries to fathom the role of mTOR signaling in diabetes 
      mellitus and its complications- diabetic cardiomyopathy, diabetic nephropathy, 
      and diabetic retinopathy and highlights mTOR as a putative target for the 
      development of novel anti-diabetic drug candidates.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Faheem
AU  - Faheem
AD  - Department of Pharmacy, Birla Institute of Technology & Science Pilani, Pilani 
      Campus, Pilani-333031, Rajasthan, India.
FAU - Sivasubrmanian, Shanthi
AU  - Sivasubrmanian S
AD  - Department of Pharmacognosy, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra 
      Institute of Higher Education and Research (DU), Chennai- 600 116, Tamil Nadu, 
      India.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Mol Pharmacol
JT  - Current molecular pharmacology
JID - 101467997
RN  - W36ZG6FT64 (Sirolimus)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
SB  - IM
MH  - Humans
MH  - Sirolimus
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - Signal Transduction
MH  - *Diabetic Nephropathies/drug therapy
MH  - *Diabetic Cardiomyopathies
MH  - *Diabetes Mellitus/drug therapy
OTO - NOTNLM
OT  - apoptosis
OT  - diabetes mellitus
OT  - diabetic cardiomyopathy
OT  - diabetic nephropathy
OT  - diabetic retinopathy
OT  - insulin resistance
OT  - mTOR
EDAT- 2022/10/07 06:00
MHDA- 2023/05/19 06:41
CRDT- 2022/10/06 02:33
PHST- 2022/04/10 00:00 [received]
PHST- 2022/08/29 00:00 [revised]
PHST- 2022/08/31 00:00 [accepted]
PHST- 2023/05/19 06:41 [medline]
PHST- 2022/10/07 06:00 [pubmed]
PHST- 2022/10/06 02:33 [entrez]
AID - CMP-EPUB-126781 [pii]
AID - 10.2174/1874467215666221005123919 [doi]
PST - ppublish
SO  - Curr Mol Pharmacol. 2023;16(5):520-529. doi: 10.2174/1874467215666221005123919.